

Review

Not peer-reviewed version

Translational Relevance of Advanced Age and Atherosclerosis in Preclinical Trials of Biotherapies for Peripheral Artery Disease

[Keith A Webster](#) *

Posted Date: 5 December 2023

doi: 10.20944/preprints202312.0244.v1

Keywords: gene therapy; cell therapy; peripheral artery disease; critical limb ischemia; clinical trials



Preprints.org is a free multidiscipline platform providing preprint service that is dedicated to making early versions of research outputs permanently available and citable. Preprints posted at Preprints.org appear in Web of Science, Crossref, Google Scholar, Scilit, Europe PMC.

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Disclaimer/Publisher's Note: The statements, opinions, and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions, or products referred to in the content.

Review

Translational Relevance of Advanced Age and Atherosclerosis in Preclinical Trials of Biotherapies for Peripheral Artery Disease

Keith A. Webster Ph.D.

Vascular Biology Institute, University of Miami, Miami, Florida

Department of Ophthalmology, Baylor College of Medicine, Houston, Texas

Abstract: Approximately 6% of adults worldwide suffer from peripheral artery disease (PAD) primarily caused by atherosclerosis of lower limb arteries. Despite optimal medicine and revascularization, many PAD patients remain symptomatic and progress to critical limb ischemia (CLI) and risk major amputation. Delivery of pro-angiogenic factors as proteins or DNA, stem or progenitor cells confers vascular regeneration and functional recovery in animal models of CLI, but the effects are not well replicated in patients and no pro-angiogenic biopharmacological procedures are approved in the EU or China. The reasons are unclear, but animal models that do not represent clinical PAD/CLI are implicated. Consequently, it is unclear whether the obstacles to clinical success lie in the toxic biochemical milieu of human CLI, or in procedures that were optimized on inappropriate models. The question is significant because the former case requires abandonment of current strategies, while the latter encourages continued optimization. These issues are discussed in the context of relevant preclinical and clinical data, and it is concluded that preclinical mouse models that include age and atherosclerosis as the only comorbidities that are consistently present and active in clinical trial patients are essential to predict clinical success. Of the reviewed materials, no biopharmacological procedure that failed in clinical trials had been tested in animal models that included advanced age and atherosclerosis relevant to PAD/CLI.

Keywords: gene therapy; cell therapy; peripheral artery disease; critical limb ischemia; clinical trials

1. Introduction

Peripheral artery disease (PAD), the third leading cause of atherosclerotic morbidity after coronary heart disease and stroke refers primarily to lower limb ischemia and includes asymptomatic lower limb PAD, intermittent claudication (IC) and critical limb ischemia (CLI). PAD affects approximately 6% of adults globally and about 8.5 million people in the United States [1, 2, 3]. Incidence is markedly age-dependent, increasing from about 5% in subjects aged 40 to 44 years to >12% at age 70 to 74, with some studies reporting IC in up to 35% of patients over 50 years of age, and 1% to 2% with CLI [4, 5, 6,]. Medical therapies to ameliorate hyperlipidaemia, hypertension, and hyperglycaemia combined with thrombolytics or fibrinolytics reduce morbidity and mortality related to cardiovascular events but have limited impact on PAD symptoms or disease progression [7, 8]. Other major risk factors for PAD include smoking, sedentary lifestyle, high BMI, and elevated systemic inflammatory markers [4,9]. Currently, only supervised walking programs and the phosphodiesterase type 3 (PDE3) inhibitor cilostazol, an antiplatelet vasodilator, provide symptomatic benefit including improved pain free walking time (PFWT). Surgical or endovascular revascularization remain primary interventions for lifestyle-limiting claudication and CLI, but this option is not available for up to 40% of CLI patients [10, 11]. Despite two decades of intense basic and translational research efforts to develop gene and/or cell therapies, no new treatments have been approved in the US or EU, leading some to question whether PAD/CLI is even amenable to such biotherapies especially gene therapy. Positive results of preclinical studies along with partial successes in some clinical trials of gene therapy, and broader successes of cell therapies, provide important information on the most promising pro-angiogenic biopharmacological strategies, but

reveal larger protocol and translation flaws, and limited predictive value of preclinical models. This review discusses the failures of earlier gene therapy clinical trials, the possible reasons for such failures, impacts on ongoing biopharmacology research for PAD and avenues to resolve the dilemmas of translation and optimization. The broad interpretation that gene therapy for PAD/CLI has failed should be tempered by the approvals and ongoing application of plasmid (p)VEGF and pHGF respectively in Russia and Japan and the significant albeit limited efficacies seen for gene therapy on some clinical parameters such as rest pain and ulcer healing. Such spasmodic efficacy suggests inadequate strategies of implementation rather than therapeutic misconceptions related to the approach, and invites further analysis and optimization.

2. Literature review

Meta-analyses of Early Clinical Trials of Genes and Cells

Whereas early meta-analyses of gene and stem cell clinical trials of patients with PAD and CLI confirm universal safety of the procedures, efficacy to enhance blood flow, prevent or delay amputation and/or death, and improve pain free walking time (PFWT) and/or quality of life have been underwhelming. Genes tested in these trials include VEGF, FGF, HIF-1a, HGF, Del-1, SDF-1, ZFP-VEGF (an engineered zinc finger transcription factor of VEGF-A), delivered by plasmid, or adenoviral vectors reviewed in [7]. Cell therapies include bone marrow mononuclear cells (BMMNC), peripheral blood mononuclear cells (PBMNC), mesenchymal stem cells (MSC), endothelial progenitor cells (EPC) and smooth muscle cells. In the first meta-analysis of Phase 2 randomized, controlled clinical trials (RCT) of gene and cell therapies for PAD/CLI, De Haro et al., [12], reported that therapeutic angiogenesis significantly improved clinical outcomes including peak PFWT relative to placebo in both PAD and CLI cohorts. The authors concluded that gene and cell therapies were safe, well tolerated and conferred significant efficacy for both PAD and CLI patients. Four years later, using similar analyses that included updated trial results, Steiner and Hammer [13] concluded from twelve PAD/CLI gene therapy RCTs and a total of 1494 patients that endpoints were not significantly improved in the majority of studies. This meta-analysis showed neither significant benefit nor harm for gene therapy across all-cause mortality, amputations, or ulcer healing, and no differences of outcomes between patients with PAD or CLI. The meta-analysis included the Talisman 201 phase II and TAMARIS phase III RTCs of plasmid (p)FGF1 (NV1FGF), the latter with 525 CLI patients was the largest worldwide gene therapy trial ever conducted [14]. Subsequent meta-analyses confirmed these results including a study with 1988 PAD/CLI patients that reported no improvement of amputation-free survival, major amputation, or death by gene therapy relative to placebo [15]. These and other disappointing results that culminated with the withdrawal in 2016 of the multinational phase III AGILITY RTC of plasmid HGF for CLI (NCT02144610) brought this phase of translational research to an end and led to predictions that clinical trials of therapeutic angiogenesis by gene therapy for PAD were over [7].

By conferring more comprehensive stimuli involving multiple cytokines and growth factors with autocrine and paracrine angiogenic effects, cell therapy has been considered potentially superior although technically more demanding than proteins or genes for promoting angiogenesis and tissue salvage in PAD. TACT (Therapeutic Angiogenesis using Cell Transplantation) was the first major cell clinical trial for PAD [16] that compared BMMNC with PBMNC. The study reported safety and significantly greater improvements in ABI, rest pain, and PFWT at 24 weeks in the BMMNC group. PROVASA (Intra-arterial administration of BMMNC in patients with CLI), a phase II RTC of intra-arterial BMMNC versus placebo, reported no difference in ABI or limb salvage but significant improvements in ulcer healing and rest pain [17]. The largest JUVENTAS (Rejuvenation EPC via transcutaneous intra-arterial supplementation) trial of CLI patients with intra-arterial of EPCs versus placebo, reported no significant differences in major amputation rate, quality of life, rest pain, ABI, or TcPO2 [18]. In a 2017 meta-analysis of autologous cell therapy that included 19 RCTs (837 patients), 7 nonrandomized trials (338 patients), and 41 noncontrolled studies (1177 patients), Rigato et al [19], reported that cell therapy reduced the risk of amputation by 37%, improved amputation-free

survival and wound healing by 18%, and 59% respectively. Cell therapy also significantly increased ABI and TcPO₂, and reduced rest pain. The authors noted that the efficacy of end points was no longer significant in placebo controlled RCTs and disappeared in RTCs with a low risk of bias. Similarly, in a 2018 meta-analysis of RCTs of autologous stem cell therapy in CLI, Xie et al., [20] reported significantly improved ABI, TcO₂, PFWT as well as ulcer healing, reduced amputation rates and increased angiogenic scores in the cell therapy group relative to controls. The analysis concluded that while cell therapy may be safe and effective, higher quality and larger RCTs are still required to support clinical application. In another recent (2019) meta-analysis of autologous stem cell therapy [21] that included 27 RCTs and 1186 patients Gao et al, reported significantly improved healing of ulcers, ABI, TcO₂, and PFWD, reduction of rest pain and minor amputation rates but no significant improvement in major limb salvage. The authors acknowledged high risk of bias and low-quality of evidence outcomes and concluded that autologous stem cell therapy may have a positive effect on “no-option” patients with PAD but did not significantly impact major limb amputation. In a meta-analysis of autologous cell therapy for CLI including 12 RCTs and 630 patients, Pu et al., [22], reported significantly improved total and major amputation rates, ABI, TcO₂, and rest pain score compared with placebo or standard care but no change in all-cause death or ulcer size and concluded that autologous cell therapy conferred benefit to CLI patients in terms of limb salvage, perfusion, and rest pain alleviation.

In their review of angiogenic cell therapy for CLI up to and including 2021 data, Beltrán-Camacho et al [23], concluded that 20 years of clinical trials with autologous stem cells confirms safety and promising efficacy but due to high variability between studies and low to moderate quality of data, it remains unclear which cells, doses, or routes of administration are optimal. One possible problem cited by several authors is that most studies are supported by sponsors with potentially conflicted interests and reporting is often incomplete and/or subjective. However, despite this, most authors agree on the safety and feasibility of cell therapies and concur that they represent a promising approach for no option CLI, a population that represents 50% of CLI patients [24, 25]. Ongoing trials are also testing secreted products such as exosomes that avoid the potential hazards and regulatory/technical demands of live autologous cell therapy and optimizing cells by preconditioning and/or genetic engineering [26, 27, 28]. Whereas autologous cell-based approaches now appear to show greater promise than gene therapy, the procedures are more expensive, labour intensive, and technically demanding.

Recent and Ongoing Clinical Trials of Genes and Cells II

With the exception of ongoing trials of pVM202 and JVS-100 (see below), the 2017 prediction by Iyler and Annex (7) that “termination of the multinational phase III AGILITY trial may well end gene therapy trials of therapeutic angiogenesis for peripheral arterial disease”, appears to have been substantially validated within the US. Despite insufficient evidence of efficacy for approval in the US, pVEGF-165 (Neovasculgen), was approved to treat CLI patients by the Russian Ministry of Healthcare in 2011 and the Ukraine equivalent in 2013. The decisions were based on positive safety/efficacy findings of pre-clinical studies and a phase IIB/III clinical trial [29-31]. Similarly, pHGF (Collategene) was approved by the Japanese Ministry of Health to treat ulcers in no-option CLI patients in 2019. This approval was based on positive results from preclinical and clinical studies including a Phase III RCT [32-35]. Clinical studies of pHGF containing two isoforms of human pHGF (HGF728 and HGF723) to treat PAD are also ongoing in the US and China. HI-PAD, a phase II RTC of pVM202 in the US was initiated in 2018 (NCT03363165) and a Phase III trial of NL003 (HGF-X7) in China was initiated in 2019 (NCT04274049). Awaited outcome results include wound healing, rest pain, and limb salvage. In a related phase III RCT of patients with painful diabetic peripheral neuropathy, Kessler et al., [36], recently reported significant alleviation of pain by pVM202 in one arm of the trial. A phase II RCT in Poland assessed safety and efficacy of a bicistronic plasmid vector expressing human VEGF165 and HGF (pIRES/VEGF165/HGF) by intramuscular injections in diabetic CLI patients [37]. Preliminary results indicate safety and efficacy with significantly increased ABI, reduced rest pain and improved vascularization assessed by computed

tomography angiography. In Beijing, China a dose escalation, safety, and tolerability phase I clinical trial of hFEG-2 delivered via intramuscular injection of Sendai virus (SeV-hFEG2) to CLI patients, initiated in 2018 is underway (NCT03668353). In another phase II RCT, Shishehbor et al reported that gene therapy with JVS-100 (pSDF-1) conferred no significant improvement in outcomes of patients undergoing revascularization [38]. The Libella gene therapy trial in Colombia is an ongoing phase I safety and tolerability trial of intravenous adeno-associated virus (AAV) expressing the human telomerase reverse transcriptase (AAV-hTERT) in CLI patients (NCT04110964). Telomerases protect against age- and cell division-dependent telomere shortening thereby delaying senescence and preserving gene function. hTERT was shown to augment VEGF-A activity and enhance the regenerative properties of endothelial progenitor cells (EPC) in vitro and in vivo. Adenovirus (Ad)-hTERT combined with Ad-VEGF was shown to enhance angiogenesis, vascular remodeling and perhaps muscle regeneration in a rat CLI model [39], and the hope is that AAV-hTERT ameliorates telomere dysfunction and augments vascular regeneration in elderly PAD patients. A parallel trial will test AAV-hTERT in Alzheimer's patients. Recruitment for the Libella trials commenced in 2019.

Predictive Value of Preclinical Models

Despite the Russian and Japanese approvals respectively of pVEGF and pHGF, and the ongoing trials of pVM202 and JVS-100, the universal failure of large phase III US based clinical trials of gene therapy for CLI has markedly dampened enthusiasm for the technology and prompted speculation on the reasons for the failures [23, 40, 41]. Possible explanations include: (1) use of single angiogenic growth factors that generate immature leaky capillaries reminiscent of pathological angiogenesis [42], (2) limitation of most interventions to stimulate only angiogenesis when revascularization may require enhanced arteriogenesis and vasculogenesis, (3) insufficient level, duration, targeting, and regulation of transgene expression, and (4) inadequate predictive value of preclinical models that do not include comorbidities of PAD/CLI patients [1, 2, 3, 43, 44]. Plasmids have been the vectors of choice for all major trials so far whereas AAV and lentiviral vectors may provide higher levels of sustained, regulable expression [45]. However, the inadequacy of preclinical models to accurately predict clinical translation stands out as a major reason for the failed gene therapy trials. Two properties of the most used mouse models that fail to replicate clinical targets include: (1) acute ischemia by femoral artery ligation and excision (FAL) that does not replicate occlusion by progressive atherosclerotic narrowing by arterial plaque (2) absence of comorbidities that determine the responsiveness of ischemic limb tissues to pro-angiogenic stimuli. Comorbidities of PAD/CLI patients that are rarely incorporated into mouse models include age, atherosclerosis, hypertension, hyperglycaemia, hyperlipidaemia, diabetes, smoking, sedentary lifestyle, elevated systemic inflammation [40, 46 - 48]. Of these advanced age and severe atherosclerosis are the only comorbidities that are consistently present in patients with clinical PAD/CLI. Other comorbidities that exacerbate clinical PAD and are variously present in clinical trial subjects are usually well-controlled by standard pharmacology that includes antithrombotic drugs, and medications to treat dyslipidaemia, hypertension, and diabetes. Such management reduces the risk of major adverse events (AMI and stroke) but does not alter the course of PAD progression or the outcome of biopharmacological (gene/cell) clinical trials [1, 3]. The average age of patients in the major phase III clinical trials of gene and cell therapies for CLI is >70 years and all patients were symptomatic with leg pain and ulcers secondary to chronic ischemia caused by atherosclerotic plaque build-up in the in-flow blood vessels [49]. For example, the mean age of patients in the TAMARIS trial was 70 years (equivalent to 25-month C57BL/6 mice), wherein atherosogenic stenoses were present in >95% of infringuinal arteries, 66% of thigh arteries, and 94% of arteries below the knee. Seventy percent of patients had more than one diseased artery, 80% were hypertensive, 60% hypercholesterolaemia, 61% former or current smokers, 53% diabetic, and 18% obese. Similar haemodynamic and angiographic patterns were typically reported in all regional areas, as well as in diabetic and non-diabetic patients. Therefore, the vasculatures of aged CLI patients with chronic, severe atherosclerosis are cannot replicate the responses to angiogenic stimulation of young healthy mice with acute ischemic damage.

Age and Atherosclerosis in Mouse CLI Models

Multiple hindlimb FAL models have been described wherein the intrinsic aptitude for vascular regeneration and functional recovery is dependent on the mouse strain [50-53]. Whereas most models are made acutely ischemic via double FAL with FA excision, new models more accurately replicate occlusion in clinical PAD [47, 54, 55]. Strain and age-dependent responses to angiogenic stimulation including roles of circulating PBMNC and BMMNC have been described [56, 57]. In the latter study, Bosch-Marce et al compared intrinsic perfusion recovery rates of young (2 months), mid-aged (8 months), and old-aged (20 months) C57BL/6 mice after FAL. Old age mice salvaged only 40% of limbs and achieved < 30% perfusion compared with young mice. The authors attributed the differences to loss of mobilization of VEGFR2+/CD34+ angiogenic cells and decreased levels of pro-angiogenic cytokines after FAL in the ischemic limbs of aged mice. Reductions of cytokines included ANGPT1 & 2 (<10%), HIF-1 α (<25%), MCP-1(<10%) , PLGF (<10%) , SCF (<10%), and SDF-1 (~10%). These trends were confirmed in other studies that reported similar ischemia but <50% recovery of limb function in 18-month versus 3-month-old mice after FAL, and diminished arteriogenesis in the ischaemic hind limbs of older mice [53, 58]. Collaterals in aged mice are less able to remodel and enlarge in response to FAL because of deficient eNOS production, and increased susceptibility of ECs and SMCs to apoptosis [59]. HIF-1 α levels are decreased in the ischaemic hind limbs of aged mice and correlate with reduced angiogenic factors, recruitment of angiogenic cells and loss of perfusion recovery after FAL [59]. Deficiency of Klotho, an anti-ageing gene in mice confers a phenotype equivalent to human aging that includes short lifespan, stunted growth, vascular calcification, and atherosclerosis, [60 – 62]. Mice with heterozygous deficiency of the klotho gene show impaired neovascularisation and perfusion recovery after FAL with markedly decreased nitric oxide release and reduction of BMMNCs [63].

Atherosclerosis progression involves accumulation of lipids, inflammatory cells, and smooth muscle cells in arterial walls that culminate in necrosis, fibrosis, and calcification [64]. Systemic inflammation is associated with severe PAD and atherothrombotic narrowing during PAD promotes changes in the circulatory system and tissues including NO-dependent compensatory responses, angiogenesis and arteriogenesis, and detrimental effects including microvascular dysfunction, myopathy, fibrosis and tissue necrosis [65, 66]. PAD is associated with reduced calf skeletal muscle area and density, increased calf muscle fat infiltration, increased oxidative stress, impaired mitochondrial activity, and smaller myofibers [67, 68]. ApoE-knockout (ApoE-/-) mice mimic traits of human atherosclerosis including inflammation and metabolism and are commonly used to simulate the effects of atherosclerosis and dyslipidaemia [69, 70]. Studies from multiple groups including the author's demonstrated that the evolution of atherosclerosis in ApoE-/- mice is paralleled by infiltration of inflammatory cells and progressive loss of mobility of BMMNCs with reduced levels of angiogenic factors including SDF-1 [71-74]. ApoE-/- C57BL/6 mice develop significant atherosclerotic lesions in the ascending aorta, carotid, femoral and popliteal arteries [75 – 77], coincident with delayed recovery from ischaemia and stunted response to angiogenic therapy [78, 79]. Couffinhal et al [80], first showed that recovery of young C57BL/6 ApoE-/- mice from hindlimb FAL was markedly attenuated relative to WT controls. Capillary density, CD-31, and VEGF that were significantly reduced in the ApoE-/- group paralleled increased infiltration of inflammatory cells, leukocytes, macrophages, and T lymphocytes. Similar results were reported by Xie et al., effects that were partially reversed by delivery of ZFP-32E, a zinc finger DNA-binding transcription factor of VEGF [81]. Using a FAL model that included Western diet and 7-month aged ApoE-/- mice, Lejay et al [82], reported more severe mitochondrial dysfunction and increased oxidative stress after FAL of ApoE-/- mice relative to control WT mice. Blunted responses of ApoE-/- mice to angiogenic stimuli have been variously attributed to dysregulated expression of miRs that regulate angiogenesis and vasculogenesis in PAD [83- 87]. Peck et al., [88], subjected 8-month-old ApoE-/- fed a normal diet to exercise training after FAL and documented responses that mimic CLI patients. They proposed that such aged ApoE-/- mice represent an appropriate hind limb ischaemia model to accurately evaluate therapeutic strategies for human PAD/CLI. By regulating

inflammation and EC angiogenesis respectively, miR-146b and miRNA-27b are implicated in the suppressed angiogenic responses of ApoE-/ mice [89, 90].

Recent and Ongoing Preclinical Trials of Genes, MiRs and NO-donors

AGGF1 (angiogenic factor with G-patch and Forkhead-associated domain-1) binds the integrin $\alpha 5\beta 1$ receptor on ECs [91], and is the earliest known regulator of multipotent hemangioblast specification, regulating haematopoiesis and differentiation of endothelial lineages [92]. AGGF1 regulates EC proliferation, adhesion, migration, and capillary tube formation [93, 94] and promotes angiogenesis as potently as VEGF-A [95]. In hindlimb ischemia mouse models pAGGF1 promoted therapeutic angiogenesis more efficiently than FGF2, [96, 97]. Transplantation of AGGF1-transduced EPCs conferred limb salvage, reperfusion, and exercise tolerance in high fat diet and db/db diabetic mouse hind-limb ischemia models [98]. AGGF1 also binds and regulates VSMC phenotypic switching, proliferation, and migration [99], and drives therapeutic angiogenesis through a pathway of integrin $\alpha 5\beta 1$, FAK, Src, and AKT signalling. The authors predict that AGGF1 through its roles in regulating vasculogenesis, angiogenesis and vascular development represents a promising target for clinical development to provide a more effective therapy for PAD/CLI [100].

Anti-angiogenic VEGF165b is an alternative spliced isoform of VEGF-A that is increased in ischemic muscle [2] and competes with pro-angiogenic isoforms of VEGF-A for binding to VEGFR2 [101]. VEGF165b is a weak agonist of VEGFR2 and the interaction lacks the downstream signalling required for an angiogenic response making it a competitive inhibitor of the VEGFR2-AKT-ERK-eNOS-NO angiogenic pathway [102- 104]. By suppressing NO production, elevated VEGF165b in muscles of PAD/CLI patients may contribute to the absence of clinical benefit seen in VEGF-A clinical trials or of NO supplementation by L-arginine in PAD patients. With the rational that PAD/CLI patients have chronically reduced responses to NO signalling and thence therapeutic angiogenesis, Kuppuswamy et al [2], recently showed that delivery of an anti-VEGF165b antibody significantly enhanced perfusion and increased microvascular density in 3 mouse PAD models with suppressed NO production including T2D and eNOS knock out mice. The authors conclude that VEGF165b is a potential therapeutic target for patients with PAD where the VEGFR2-eNOS-NO pathway is impaired. The same group recently identified the IL-21 receptor (IL-21R) as causally linked to the differential responses of C57BL/6 versus Balb/c mice to hindlimb ischemia. High IL-21R expression in ECs of ischemic hindlimbs in C57BL/6 mice coincided with enhanced perfusion recovery whereas low IL-21R expression in Balb/C correlated with sustained perfusion deficit and greater tissue loss during HLI [50]. Genetic support linking the IL-21R with human PAD prompted the authors to target IL-21R for nitric oxide-independent, angiogenesis in PAD [1].

MiR-15 and -16 belong to an extended miR-16 family that bind to Tie2 mRNA coding sequences (CDSs) and regulate angiogenesis by targeting VEGFR2 and FGFR1 [105]. The miRs are conserved between humans and mice [106]. MiR-15a and -16 are increased in serum and circulating proangiogenic cells (PACs) of CLI patients wherein serum concentrations predict amputation at 1 year post revascularization [107]. *Ex vivo* transfection with miR-15a/16 inhibitors increase the potential of human PACs to induce therapeutic angiogenesis in mouse PAD models [107] and therapeutic angiogenesis is impaired in mice with *miR-15a* gene knock-in [108]. Local adenoviral delivery of a 15a/16 decoy increased Tie2 levels in ischemic skeletal muscle, improved perfusion recovery and reduced toe necrosis. The results support further development of Ad-Decoy-15a/16 to treat human PAD/CLI.

MiR-150. Using next-generation sequencing and quantitative reverse transcription polymerase chain reaction analyses Desjarlais et al., [109], reported that decreased levels of the proangiogenic microRNA miR-150 in ApoE-/ mice conferred decreased Src, eNOS and Akt activities that was mechanistically associated with inefficient neovascularization following FAL. The effects were normalized by forced expression of a miR-150 mimic that the authors propose to represent a novel therapeutic strategy to improve ischemia-induced neovascularization in atherosclerotic conditions. However, this model does not represent the average age or severity of atherosclerosis of human CLI.

AAV-PFKFB3 delivery was shown to salvage limbs, increase perfusion and improve muscle contractile function following FAL in BALB/c mice [110]. The model mimics CLI patients wherein compromised mitochondria and inflexible metabolism exacerbate myopathy. The authors report that the glycolytic enzyme 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 (PFKFB3) was markedly induced in transgenic mice with defective mitochondrial metabolism caused by accumulated mutations in mtDNA, and this conferred resistance to ischemic myopathy by enhancing glycolysis and maintaining ATP in ischemic muscle. Muscles from CLI patients were shown to contain lower PFKFB3 relative to normal or claudication muscles and decreased glycolytic flux capacity. The results support reduced glycolytic flux as a common characteristic of failing CLI patient limb skeletal muscle that may be responsive to gene therapy with AAV-PFKFB3.

MPC-1011 an NO-donor stimulates angiogenesis and arteriogenesis and improves hindlimb ischemia via a cGMP-dependent pathway involving VEGF and SDF-1 α . [111]. Atherosclerosis-impaired NO production and associated vascular dysfunction is well-documented in PAD patients and animal models [112 – 117]. Preclinical studies and small clinical trials confirm increased PFWT in PAD patients via NO augmentation with beetroot juice, derivates of dark chocolate, MitoQ, a mitochondria-targeted antioxidant, and PDE-V inhibitor sildenafil (118-122).

3. Summary and conclusions

Whereas the positive albeit variable results of cell therapies for PAD/CLI encourage further testing to optimize and consolidate cell types and procedures, the limited efficacies revealed by large clinical trials of gene therapy have led to reduced enthusiasm for continued development of this approach. However, gene therapy clinical trials were based on preclinical models that lacked predictive value for clinical translation, and much evidence suggests that more predictive models would identify different protocols with increased likelihood of clinical success. At minimum such models would preclude expensive, time and labour-intensive clinical development of products that were predestined to fail. Importantly, all phase III gene therapy trials were limited to plasmid gene delivery, whereas more efficient viral delivery (AAV/Lentivirus) allows higher expression, targeting and defined duration of transgene expression, as demonstrated in a PAD model by the author's group [45] and in other indications [123, 124, 125]. Newer gene therapy approaches including those listed above may benefit from preliminary testing in preclinical models that include advanced age and atherosclerosis (ApoE-/- mice) prior to clinical development. Such an application while arduous is not as labour intensive, time consuming and expensive as the build-up and implementation of clinical trials; by some estimates the cost of TAMARIS was > \$25M. Whereas FDA IND approvals for cardiovascular indications require two animal species, relevant co-morbidities are not required and not routinely included.

Advanced age and atherosclerosis create toxic environments that render host tissues, vascular beds, and resident cells resistant to vascular regeneration and tissue salvage. Heightened local and systemic inflammation, suppressed expression of angiogenic and arteriogenic growth factors and cytokines, impaired NO production, dysregulated miRs that drive angiogenesis and arteriogenesis, microvascular dysfunction, increased oxidative stress, and impaired metabolic regulation including mitochondrial and glycolytic dysfunctions may contribute to muted responses to vasculogenesis. The effects worsen in parallel with age and severity of atherosclerosis. CLI patients in the major failed clinical trials of gene therapy were of advanced age (mean of 70 years) with severe atherosclerosis. To our knowledge none of the angiogenic genes subject to clinical trial were tested in preclinical models that included equivalent backgrounds of advanced age and atherosclerosis. Mouse PAD/CLI models that include age and/or atherosclerosis show markedly reduced responses to both gene and cell treatments. Application of such more inclusive models including surgical techniques that more closely mimic the target population of PAD patients is predicted to provide much needed information to optimize both gene and cell therapies for clinical application.

Funding: Supported by NIH grant # 5R24EY028764.

Conflicts of Interest. The author declares no conflict of interest in the subject matter of the review.

References

1. Annex BH, Cooke JP. New Directions in Therapeutic Angiogenesis and Arteriogenesis in Peripheral Arterial Disease. *Circ Res.* **2021** 128(12), 1944-1957.
2. Kuppuswamy S, Annex BH, Ganta VC. Targeting Anti-Angiogenic VEGF165b-VEGFR1 Signaling Promotes Nitric Oxide Independent Therapeutic Angiogenesis in Preclinical Peripheral Artery Disease Models. *Cells.* **2022** 11(17), 2676.
3. Ganta VC, Annex BH. Peripheral vascular disease: preclinical models and emerging therapeutic targeting of the vascular endothelial growth factor ligand-receptor system. *Expert Opin Ther Targets.* **2021** 25(5), 381-391.
4. Fowkes FG, Rudan D, Rudan I, Aboyans V, Denenberg JO, McDermott MM, Norman PE, Sampson UK, Williams LJ, Mensah GA, Criqui MH. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. *Lancet.* **2013**, 382, 1329-40.
5. Rooke TW, Hirsch AT, Misra S, Sidawy AN, Beckman JA, Findeiss L, Golzarian J, Gornik HL, Jaff MR, Moneta GL, Olin JW, Stanley JC, White CJ, White JV, Zierler RE; a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol.* **2013**, 61, 1555-70.
6. Hirsch AT, Haskal ZJ, Hertzer NR, et al. Guidelines for the Management of Patients With Peripheral Arterial Disease. *Circulation.* **2006**, 113, 463-654.
7. Iyer SR, Annex BH. Therapeutic Angiogenesis for Peripheral Artery Disease: Lessons Learned in Translational Science. *JACC Basic Transl Sci.* **2017**, 2(5), 503-512.
8. Mohler ER 3rd, Hiatt WR, Creager MA. Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease. *Circulation.* **2003**, 108(12), 1481-6.
9. Criqui MH, Aboyans V. Epidemiology of peripheral artery disease. *Circ Res.* **2015**, 116(9):1509-26.
10. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG; TASC II Working Group. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). *J Vasc Surg.* **2007**, 45 Suppl S, S5-67.
11. Lawall H, Bramlage P, Amann B. Stem cell and progenitor cell therapy in peripheral artery disease. A critical appraisal. *Thromb Haemost.* **2010**, 103(4), 696-709.
12. De Haro J, Acin F, Lopez-Quintana A, Florez A, Martinez-Aguilar E, Varela C. Meta-analysis of randomized, controlled clinical trials in angiogenesis: gene and cell therapy in peripheral arterial disease. *Heart Vessels.* **2009**, 24(5), 321-8.
13. Hammer A, Steiner S. Gene therapy for therapeutic angiogenesis in peripheral arterial disease - a systematic review and meta-analysis of randomized, controlled trials. *Vasa.* **2013** 42(5), 331-9.
14. Belch J, Hiatt WR, Baumgartner I, Driver IV, Nikol S, Norgren L, Van Belle E; TAMARIS Committees and Investigators. Effect of fibroblast growth factor NV1FGF on amputation and death: a randomised placebo-controlled trial of gene therapy in critical limb ischaemia. *Lancet.* **2011** 377(9781), 1929-37.
15. Forster R, Liew A, Bhattacharya V, Shaw J, Stansby G. Gene therapy for peripheral arterial disease. *Cochrane Database Syst Rev.* **2018** 10(10), CD012058.
16. Tateishi-Yuyama E, Matsubara H, Murohara T, et al. Therapeutic Angiogenesis using Cell Transplantation (TACT) Study Investigators. Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial. *Lancet.* **2002** 360(9331):427-35.
17. Walter DH, Krakenberg H, Balzer JO, Kalka C, et al. PROVASA Investigators. Intraarterial administration of bone marrow mononuclear cells in patients with critical limb ischemia: a randomized-start, placebo-controlled pilot trial (PROVASA). *Circ Cardiovasc Interv.* **2011** 4(1), 26-37.
18. Teraa M, Sprengers RW, Schutgens RE et al. Effect of repetitive intra-arterial infusion of bone marrow mononuclear cells in patients with no-option limb ischemia: the randomized, double-blind, placebo-controlled Rejuvenating Endothelial Progenitor Cells via Transcutaneous Intra-arterial Supplementation (JUVENTAS) trial. *Circulation.* **2015** 131(10), 851-60.
19. Rigato M, Monami M, Fadini GP. Autologous Cell Therapy for Peripheral Arterial Disease: Systematic Review and Meta-Analysis of Randomized, Nonrandomized, and Noncontrolled Studies. *Circ Res.* **2017** 120(8), 1326-1340.
20. Xie B, Luo H, Zhang Y, Wang Q, Zhou C, Xu D., *Stem Cells Int.* **2018** 2018, 7528464.
21. Gao W, Chen D, Liu G, Ran X. Autologous stem cell therapy for peripheral arterial disease: a systematic review and meta-analysis of randomized controlled trials. *Stem Cell Res Ther.* **2019** 10(1), 140.
22. Pu H, Huang Q, Zhang X, Wu Z, et al. meta-analysis of randomized controlled trials on therapeutic efficacy and safety of autologous cell therapy for atherosclerosis obliterans. *J Vasc Surg.* **2022** 75(4), 1440-1449.
23. Beltrán-Camacho L, Rojas-Torres M, Durán-Ruiz MC. Current Status of Angiogenic Cell Therapy and Related Strategies Applied in Critical Limb Ischemia. *Int J Mol Sci.* **2021** 22(5), 2335.

24. Ruiz-Salmeron R, de la Cuesta-Diaz A, Constantino-Bermejo M, et al. Angiographic demonstration of neoangiogenesis after intra-arterial infusion of autologous bone marrow mononuclear cells in diabetic patients with critical limb ischemia. *Cell Transplant.* **2011**, *20*(10), 1629-39.

25. De Angelis B, Gentile P, Orlandi F, Bocchini I, Di Pasquali C, Agovino A, Gizzi C, Patrizi F, Scioli MG, Orlandi A, Cervelli V. Limb rescue: a new autologous-peripheral blood mononuclear cells technology in critical limb ischemia and chronic ulcers. *Tissue Eng Part C Methods.* **2015** *21*(5), 423-35.

26. O'Neill KM, Campbell DC, Edgar KS, Gill EK, et al. NOX4 is a major regulator of cord blood-derived endothelial colony-forming cells which promotes post-ischaemic revascularization. *Cardiovasc Res.* **2020** *116*(2), 393-405.

27. Hu X, Wu R, Jiang Z, et al. Leptin signaling is required for augmented therapeutic properties of mesenchymal stem cells conferred by hypoxia preconditioning. *Stem Cells.* **2014** *32*(10), 2702-13.

28. Ma Q, Xia X, Tao Q, et al.. Profound Actions of an Agonist of Growth Hormone-Releasing Hormone on Angiogenic Therapy by Mesenchymal Stem Cells. *Arterioscler Thromb Vasc Biol.* **2016** *36*(4), 663-672.

29. Deev RV, Bozo IY, Mzhavanadze ND, et al.. pCMV-vegf165 Intramuscular Gene Transfer is an Effective Method of Treatment for Patients With Chronic Lower Limb Ischemia. *J Cardiovasc Pharmacol Ther.* **2015** *20*(5), 473-82.

30. Deev R, Plaksa I, Bozo I, Isaev A. Results of an International Postmarketing Surveillance Study of pl-VEGF165 Safety and Efficacy in 210 Patients with Peripheral Arterial Disease. *Am J Cardiovasc Drugs.* **2017** *17*(3), 235-242.

31. Deev R, Plaksa I, Bozo I, et al. Results of 5-year follow-up study in patients with peripheral artery disease treated with PL-VEGF165 for intermittent claudication. *Ther Adv Cardiovasc Dis.* **2018** *12*(9), 237-246.

32. Shigematsu H, Yasuda K, Iwai T, et al.. Randomized, double-blind, placebo-controlled clinical trial of hepatocyte growth factor plasmid for critical limb ischemia. *Gene Ther.* **2010** *17*(9), 1152-61.

33. Ylä-Herttula S. Gene Therapy of Critical Limb Ischemia Enters Clinical Use. *Mol Ther.* **2019** *27*(12), 2053.

34. Morishita R, Shimamura M, Takeya Y, et al. Combined Analysis of Clinical Data on HGF Gene Therapy to Treat Critical Limb Ischemia in Japan. *Curr Gene Ther.* **2020** *20*(1), 25-35.

35. Sanada F, Fujikawa T, Shibata K, et al. Therapeutic Angiogenesis Using HGF Plasmid. *Ann Vasc Dis.* **2020** *13*(2), 109-115.

36. Kessler JA, Shaibani A, Sang CN, et al. Gene therapy for diabetic peripheral neuropathy: A randomized, placebo-controlled phase III study of VM202, a plasmid DNA encoding human hepatocyte growth factor. *Clin Transl Sci.* **2021** *14*(3), 1176-1184.

37. Barć P, Antkiewicz M, Śliwa B, et al. Double VEGF/HGF Gene Therapy in Critical Limb Ischemia Complicated by Diabetes Mellitus. *J Cardiovasc Transl Res.* **2021** *14*(3), 409-415.

38. Shishelbor MH, Rundback J, Bunte M, et al. SDF-1 plasmid treatment for patients with peripheral artery disease (STOP-PAD): Randomized, double-blind, placebo-controlled clinical trial. *Vasc Med.* **2019** *24*(3), 200-207.

39. Zaccagnini G, Gaetano C, Della Pietra L, et al. Telomerase mediates vascular endothelial growth factor-dependent responsiveness in a rat model of hind limb ischemia. *J Biol Chem.* **2005** *280*(15), 14790-8.

40. Golledge J. Update on the pathophysiology and medical treatment of peripheral artery disease. *Nat Rev Cardiol.* **2022** *19*(7), 456-474.

41. Han J, Luo L, Marcelina O, Kasim V, Wu S. Therapeutic angiogenesis-based strategy for peripheral artery disease. *Theranostics.* **2022** *12*(11), 5015-5033.

42. Rebar EJ, Huang Y, Hickey R, et al. Induction of angiogenesis in a mouse model using engineered transcription factors. *Nat Med.* **2002** *8*(12), 1427-32.

43. Campia U, Gerhard-Herman M, Piazza G, Goldhaber SZ. Peripheral Artery Disease: Past, Present, and Future. *Am J Med.* **2019** *132*(10), 1133-1141.

44. Firnhaber JM, Powell CS. Lower Extremity Peripheral Artery Disease: Diagnosis and Treatment. *Am Fam Physician.* **2019** *99*(6), 362-369.

45. Boden J, Lassance-Soares RM, Wang H, et al. Vascular Regeneration in Ischemic Hindlimb by Adeno-Associated Virus Expressing Conditionally Silenced Vascular Endothelial Growth Factor. *J Am Heart Assoc.* **2016** *5*(6):e001815.

46. Krishna SM, Omer SM, Golledge J. Evaluation of the clinical relevance and limitations of current pre-clinical models of peripheral artery disease. *Clin Sci (Lond).* **2016** *130*(3), 127-50.

47. Krishna SM, Omer SM, Li J, et al. Development of a two-stage limb ischemia model to better simulate human peripheral artery disease. *Sci Rep.* **2020** *10*(1), 3449.

48. Golledge J, Fernando ME, Armstrong DG. Current Management of Peripheral Artery Disease: Focus on Pharmacotherapy. *Drugs.* **2022** *82*(11), 1165-1177.

49. Annex BH. Therapeutic angiogenesis for critical limb ischaemia. *Nat Rev Cardiol.* **2013** *10*(7), 387-96.

50. Peck MA, Crawford RS, Abularrage CJ, Patel VI, Conrad MF, Yoo JH, Watkins MT, Albadawi H. A functional murine model of hindlimb demand ischemia. *Ann Vasc Surg.* **2010** *24*(4), 532-7.

51. Krishna SM, Omer SM, Golledge J. Evaluation of the clinical relevance and limitations of current pre-clinical models of peripheral artery disease. *Clin Sci (Lond)*. 2016;130(3):127-50.
52. Lin JB, Phillips EH, Riggins TE, et al. Imaging of small animal peripheral artery disease models: recent advancements and translational potential. *Int J Mol Sci*. 2015;16(5):11131-77.
53. Lotfi S, Patel AS, Mattock K, et al. Towards a more relevant hind limb model of muscle ischaemia. *Atherosclerosis*. 2013;227(1):1-8.
54. Yan K, Zheng J, Zöllner FG, et al. A Modified Surgical Model of Hind Limb Ischemia in ApoE-/- Mice using a Miniature Incision. *J Vis Exp*. 2021;13:171.
55. Aref Z, de Vries MR, Quax PHA. Variations in Surgical Procedures for Inducing Hind Limb Ischemia in Mice and the Impact of These Variations on Neovascularization Assessment. *Int J Mol Sci*. 2019;20(15):3704.
56. Shaked Y, Bertolini F, Man S, et al. Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis; Implications for cellular surrogate marker analysis of antiangiogenesis. *Cancer Cell*. 2005;7(1):101-11.
57. Bosch-Marce M, Okuyama H, Wesley JB, et al. Effects of aging and hypoxia-inducible factor-1 activity on angiogenic cell mobilization and recovery of perfusion after limb ischemia. *Circ Res*. 2007;101(12):1310-8.
58. Westvik TS, Fitzgerald TN, Muto A, et al. Limb ischemia after iliac ligation in aged mice stimulates angiogenesis without arteriogenesis. *J Vasc Surg*. 2009;49(2):464-73.
59. Wang J, Peng X, Lassance-Soares RM, et al. Aging-induced collateral dysfunction: impaired responsiveness of collaterals and susceptibility to apoptosis via dysfunctional eNOS signaling. *J Cardiovasc Transl Res*. 2011;4(6):779-89.
60. Kuro-o M, Matsumura Y, Aizawa H, et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. *Nature*. 1997;390(6655):45-51.
61. Fukino K, Suzuki T, Saito Y, et al. Regulation of angiogenesis by the aging suppressor gene klotho. *Biochem Biophys Res Commun*. 2002;293(1):332-7.
62. Bosch-Marce M, Okuyama H, Wesley JB, et al. Effects of aging and hypoxia-inducible factor-1 activity on angiogenic cell mobilization and recovery of perfusion after limb ischemia. *Circ Res*. 2007;101(12):1310-8.
63. Shimada T, Takeshita Y, Murohara T, et al. Angiogenesis and vasculogenesis are impaired in the precocious-aging klotho mouse. *Circulation*. 2004;110(9):1148-55.
64. Libby P. The changing landscape of atherosclerosis. *Nature*. 2021;592(7855):524-533.
65. Krishna SM, Omer SM, Golledge J. Evaluation of the clinical relevance and limitations of current pre-clinical models of peripheral artery disease. *Clin Sci (Lond)*. 2016;130(3):127-50.
66. Krishna SM, Moxon JV, Golledge J. A review of the pathophysiology and potential biomarkers for peripheral artery disease. *Int J Mol Sci*. 2015;16(5):11294-322.
67. McDermott MM, Ferrucci L, Gonzalez-Freire M, et al. Skeletal Muscle Pathology in Peripheral Artery Disease: A Brief Review. *Arterioscler Thromb Vasc Biol*. 2020;40(11):2577-2585.
68. Burgmaier M, Schutters K, Willems B, et al. AnxA5 reduces plaque inflammation of advanced atherosclerotic lesions in apoE(-/-) mice. *J Cell Mol Med*. 2014;18(10):2117-24.
69. Xiong W, Wang X, Dai D, Zhang B, Lu L, Tao R. The anti-inflammatory vasostatin-2 attenuates atherosclerosis in ApoE-/- mice and inhibits monocyte/macrophage recruitment. *Thromb Haemost*. 2017;117(2):401-414.
70. Kahles F, Liberman A, Halim C, et al. The incretin hormone GIP is upregulated in patients with atherosclerosis and stabilizes plaques in ApoE-/- mice by blocking monocyte/macrophage activation. *Mol Metab*. 2018;14:150-157.
71. Xu Q, Wang J, He J, et al. Impaired CXCR4 expression and cell engraftment of bone marrow-derived cells from aged atherogenic mice. *Atherosclerosis*. 2011;219(1):92-9.
72. Qin H, Liu P, Lin S. Effects of Astragaloside IV on the SDF-1/CXCR4 Expression in Atherosclerosis of apoE(-/-) Mice Induced by Hyperlipaemia. *Evid Based Complement Alternat Med*. 2015;2015:385154.
73. Heidt T, Sager HB, Courties G, et al. Chronic variable stress activates hematopoietic stem cells. *Nat Med*. 2014;20(7):754-758.
74. Schmitt MM, Megens RT, Zernecke A, et al. Endothelial junctional adhesion molecule-a guides monocytes into flow-dependent predilection sites of atherosclerosis. *Circulation*. 2014;129(1):66-76.
75. Seo HS, Lombardi DM, Polinsky P, et al. Peripheral vascular stenosis in apolipoprotein E-deficient mice. Potential roles of lipid deposition, medial atrophy, and adventitial inflammation. *Arterioscler Thromb Vasc Biol*. 1997;17(12):3593-601.
76. Rodriguez-Menocal L, Wei Y, Pham SM, et al. A novel mouse model of in-stent restenosis. *Atherosclerosis*. 2010;209(2):359-66.
77. Cesar L, Suarez SV, Adi J, et al. An essential role for diet in exercise-mediated protection against dyslipidemia, inflammation and atherosclerosis in ApoE-/- mice. *PLoS One*. 2011;6(2):e17263.
78. Balestrieri ML, Lu SJ, de Nigris F, et al. Therapeutic angiogenesis in diabetic apolipoprotein E-deficient mice using bone marrow cells, functional hemangioblasts and metabolic intervention. *Atherosclerosis*. 2010;209(2):403-14.

79. Kang J, Albadawi H, Patel VI, et al. Apolipoprotein E-/- mice have delayed skeletal muscle healing after hind limb ischemia-reperfusion. *J Vasc Surg.* **2008** *48*(3), 701-8.

80. Couffinhal T, Silver M, Kearney M, et al. Impaired collateral vessel development associated with reduced expression of vascular endothelial growth factor in ApoE-/- mice. *Circulation.* **1999** *99*(24), 3188-98.

81. Xie D, Li Y, Reed EA, Odronic S et al. An engineered vascular endothelial growth factor-activating transcription factor induces therapeutic angiogenesis in ApoE knockout mice with hindlimb ischemia. *J Vasc Surg.* **2006** *44*(1), 166-75.

82. Lejay A, Charles AL, Georg I et al. Critical Limb Ischaemia Exacerbates Mitochondrial Dysfunction in ApoE-/- Mice Compared with ApoE+/+ Mice, but N-acetyl Cysteine still Confers Protection. *Eur J Vasc Endovasc Surg.* **2019** *58*(4), 576-582.

83. Feinberg MW, Moore KJ. MicroRNA Regulation of Atherosclerosis. *Circ Res.* **2016** *118*(4), 703-20.

84. Shan Z, Yao C, Li ZL, et al. Differentially expressed microRNAs at different stages of atherosclerosis in ApoE-deficient mice. *Chin Med J (Engl).* **2013** *126*(3), 515-20.

85. Vogiatzi G, Oikonomou E, Deftereos S, et al. Peripheral artery disease: a micro-RNA-related condition? *Curr Opin Pharmacol.* **2018** *39*, 105-112.

86. Pérez-Cremades D, Cheng HS, Feinberg MW. Noncoding RNAs in Critical Limb Ischemia. *Arterioscler Thromb Vasc Biol.* **2020** *40*(3), 523-533.

87. Gao L, Zeng H, Zhang T, Mao C, Wang Y, Han Z, Chen K, Zhang J, Fan Y, Gu J, Wang C. MicroRNA-21 deficiency attenuated atherogenesis and decreased macrophage infiltration by targeting Dusp8. *Atherosclerosis.* **2019** *291*, 78-86.

88. Peck MA, Crawford RS, Abularrage CJ, et al. A functional murine model of hindlimb demand ischemia. *Ann Vasc Surg.* **2010** *24*(4), 532-7.

89. Desjarlais M, Dussault S, Rivard F et al. Forced expression of microRNA-146b reduces TRAF6-dependent inflammation and improves ischemia-induced neovascularization in hypercholesterolemic conditions. *Atherosclerosis.* **2019** *289*, 73-84.

90. Qun L, Wenda X, Weihong S, et al. miRNA-27b modulates endothelial cell angiogenesis by directly targeting Naa15 in atherogenesis. *Atherosclerosis.* **2016** *254*, 184-192.

91. Wang J, Peng H, Timur AA, et al. Receptor and Molecular Mechanism of AGGF1 Signaling in Endothelial Cell Functions and Angiogenesis. *Arterioscler Thromb Vasc Biol.* **2021** *41*(11), 2756-2769.

92. Li L, Chen D, Li J, Wang X, et al. Aggf1 acts at the top of the genetic regulatory hierarchy in specification of hemangioblasts in zebrafish. *Blood.* **2014** *123*(4), 501-8..

93. Fan C, Chen Q, Wang QK. Functional role of transcriptional factor TBX5 in pre-mRNA splicing and Holt-Oram syndrome via association with SC35. *J Biol Chem.* **2009** *284*(38), 25653-63.

94. Zhang T, Yao Y, Wang J, et al. Haploinsufficiency of Klippel-Trenaunay syndrome gene Aggf1 inhibits developmental and pathological angiogenesis by inactivating PI3K and AKT and disrupts vascular integrity by activating VE-cadherin. *Hum Mol Genet.* **2016** *25*(23), 5094-5110.

95. Tian XL, Kadaba R, You SA, et al. Identification of an angiogenic factor that when mutated causes susceptibility to Klippel-Trenaunay syndrome. *Nature.* **2004** *427*(6975), 640-5.

96. Lu Q, Yao Y, Yao Y et al. Angiogenic factor AGGF1 promotes therapeutic angiogenesis in a mouse limb ischemia model. *PLoS One.* **2012** *7*(10):e46998.

97. Wang J, Peng H, Timur AA, et al. Receptor and Molecular Mechanism of AGGF1 Signaling in Endothelial Cell Functions and Angiogenesis. *Arterioscler Thromb Vasc Biol.* **2021** *41*(11), 2756-2769.

98. Yao Y, Li Y, Song Q, et al. Angiogenic Factor AGGF1-Primed Endothelial Progenitor Cells Repair Vascular Defect in Diabetic Mice. *Diabetes.* **2019** *68*(8), 1635-1648.

99. Yu Y, Li Y, Peng H, et al. Angiogenic factor AGGF1 blocks neointimal formation after vascular injury via interaction with integrin α 7 on vascular smooth muscle cells. *J Biol Chem.* **2022** *298*(4), 101759.

100. Wang J, Peng H, Timur AA, et al. Receptor and Molecular Mechanism of AGGF1 Signaling in Endothelial Cell Functions and Angiogenesis. *Arterioscler Thromb Vasc Biol.* **2021** *41*(11), 2756-2769.

101. Harper SJ, Bates DO. VEGF-A splicing: the key to anti-angiogenic therapeutics? *Nat Rev Cancer.* **2008** *8*(11), 880-7.

102. Rennel ES, Varey AH, Churchill AJ, et al. VEGF(121)b, a new member of the VEGF(xxx)b family of VEGF-A splice isoforms, inhibits neovascularisation and tumour growth in vivo. *Br J Cancer.* **2009** *101*(7), 1183-93.

103. Catena R, Larzabal L, Larrayoz M, et al VEGF_{121b} and VEGF_{165b} are weakly angiogenic isoforms of VEGF-A. *Mol Cancer.* **2010** *9*:320.

104. Kawamura H, Li X, Harper SJ, Bates DO, Claesson-Welsh L. Vascular endothelial growth factor (VEGF)-A165b is a weak in vitro agonist for VEGF receptor-2 due to lack of coreceptor binding and deficient regulation of kinase activity. *Cancer Res.* **2008** *68*(12), 4683-92.

105. Chamorro-Jorgues A, Araldi E, Penalva LO, et al. MicroRNA-16 and microRNA-424 regulate cell-autonomous angiogenic functions in endothelial cells via targeting vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1. *Arterioscler Thromb Vasc Biol.* **2011** *31*(11), 2595-606.

106. Yue J, Tigyi G. Conservation of miR-15a/16-1 and miR-15b/16-2 clusters. *Mamm Genome*. **2010** 21(1-2), 88-94.
107. Spinetti G, Fortunato O, Caporali A, et al. MicroRNA-15a and microRNA-16 impair human circulating proangiogenic cell functions and are increased in the proangiogenic cells and serum of patients with critical limb ischemia. *Circ Res*. **2013** 112(2), 335-46.
108. Yin KJ, Olsen K, Hamblin M, et al. Vascular endothelial cell-specific microRNA-15a inhibits angiogenesis in hindlimb ischemia. *J Biol Chem*. **2012** 287(32), 27055-64.
109. Desjarlais M, Dussault S, Dhahri W, et al. MicroRNA-150 Modulates Ischemia-Induced Neovascularization in Atherosclerotic Conditions. *Arterioscler Thromb Vasc Biol*. **2017** 37(5), 900-908.
110. Ryan TE, Schmidt CA, Tarpey MD, et al. PFKFB3-mediated glycolysis rescues myopathic outcomes in the ischemic limb. *JCI Insight*. **2020** 5(18): e139628.
111. Gomes de Almeida Schirmer B, Crucet M, Stivala S, et al. The NO-donor MPC-1011 stimulates angiogenesis and arteriogenesis and improves hindlimb ischemia via a cGMP-dependent pathway involving VEGF and SDF-1 α . *Atherosclerosis*. **2020** 304:30-38.
112. Loffredo L, Pignatelli P, Cangemi R, et al. Imbalance between nitric oxide generation and oxidative stress in patients with peripheral arterial disease: effect of an antioxidant treatment. *J Vasc Surg*. **2006** 44(3), 525-30.
113. Allen JD, Giordano T, Kevil CG. Nitrite and nitric oxide metabolism in peripheral artery disease. *Nitric Oxide*. **2012** 26(4), 217-22.
114. Hong FF, Liang XY, Liu W, Lv S, He SJ, Kuang HB, Yang SL. Roles of eNOS in atherosclerosis treatment. *Inflamm Res*. **2019** 68(6), 429-441.
115. Ismaeel A, Papoutsi E, Miserlis D, et al. The Nitric Oxide System in Peripheral Artery Disease: Connection with Oxidative Stress and Biopterins. *Antioxidants (Basel)*. **2020** 9(7), 590.
116. Woessner M, VanBruggen MD, Pieper CF, et al. Beet the Best? *Circ Res*. **2018** 123(6), 654-659.
117. Kenjale AA, Ham KL, Stabler T, et al. Dietary nitrate supplementation enhances exercise performance in peripheral arterial disease. *J Appl Physiol*. **2011** 110(6), 1582-91.
118. Loffredo L, Perri L, Catasca E, et al. Dark chocolate acutely improves walking autonomy in patients with peripheral artery disease. *J Am Heart Assoc*. **2014** 3(4):e001072.
119. McDermott MM, Criqui MH, Domanchuk K, et al. Cocoa to Improve Walking Performance in Older People With Peripheral Artery Disease: The COCOA-PAD Pilot Randomized Clinical Trial. *Circ Res*. **2020** 126(5), 589-599.
120. Park SY, Pekas EJ, Headid RJ, et al. Acute mitochondrial antioxidant intake improves endothelial function, antioxidant enzyme activity, and exercise tolerance in patients with peripheral artery disease. *Am J Physiol Heart Circ Physiol*. **2020** 319(2), H456-H467.
121. Kotalczyk A, Vallabhaneni SR, Lip GYH. Review new concepts in pharmacotherapy for peripheral arterial disease. *Curr Opin Cardiol*. **2021** 36(6), 720-726.
122. Omarjee L, Le Pabic E, Custaud MA, et al. Effects of sildenafil on maximum walking time in patients with arterial claudication: The ARTERIOFIL study. *Vascul Pharmacol*. **2019** 118-119, 106563.
123. Silver E, Argiro A, Hong K, Adler E. Gene therapy vector-related myocarditis. *Int J Cardiol*. **2023** 131617.
124. Naso MF, Tomkowicz B, Perry WL 3rd, Strohl WR. Adeno-Associated Virus (AAV) as a Vector for Gene Therapy. *BioDrugs*. **2017** 31(4), 317-334.
125. Mendell JR, Al-Zaidy SA, Rodino-Klapac LR, et al. Current Clinical Applications of In Vivo Gene Therapy with AAVs. *Mol Ther*. **2021** 29(2), 464-488.